ELASTIN-BASED COPOLYMERS AND METHOD OF USING

• US 20140356519A1
• Filed: 06/18/2014
• Published: 12/04/2014
• Est. Priority Date: 06/09/2006
• Status: Abandoned Application

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Inventors: Hossainy, Syed F.A., Trollsas, Mikael, Glauser, Thierry, Tang, Yiwen
• Application Number:
  US14/308,444
• Publication Number:
  US 20140356519A1
• Time in Patent Office: Days
• US Class Current: 427/2.25
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/39 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: A61L 2300/25 Peptides having up to 20 amino acids in a defined sequence
• CPC Class Codes: A61L 2420/02 Methods for coating medical devices
• CPC Class Codes: A61L 27/227 Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 31/047 Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: B05D 3/007 : After-treatment
• CPC Class Codes: C07K 14/001 : by chemical synthesis
• CPC Class Codes: C08H 1/00 : Macromolecular products derived from proteins food proteins A23; glue, gelatine C09H
• CPC Class Codes: Y10T 428/3154 : Of fluorinated addition polymer from unsaturated monomers
• CPC Class Codes: Y10T 428/31909 : Next to second addition polymer from unsaturated monomers

Abstract

A copolymer comprising a block of an elastin pentapeptide and method of making and using the copolymer are provided.

Claims

1-40. -40. (canceled)

41. A method of forming a coating comprising an elastin-based copolymer on a medical device, comprising

providing an acidic solution having pH below 7 comprising the elastin-based copolymer,

applying the solution to the medical device to form a layer of the solution on the medical device, and

applying a solution of buffer having a pH above 7 to the medical device to cause the elastin-based copolymer to come out to form the coating comprising the elastin-based copolymer.

42. The method of claim 41, wherein the acidic solution further comprises a bioactive agent.

43. The method of claim 42, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutase mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3 -hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), γ

-hiridun, clobetasol, mometasone, pimecrolimus, imatinib mesylate, midostaurin, and combinations thereof.

44. The method of claim 41, wherein the an elastin-based copolymer is a block copolymer comprising a block comprising an elastin pentapeptide (A) and a hydrophilic block (B), wherein the elastin pentapeptide is VGVPG (SEQ ID NO:

1).

45. The method of claim 44, wherein the block copolymer is an ABA type triblock copolymer.

46. The method of claim 44, wherein the hydrophilic block comprises lysine.

47. The method of claim 44, wherein the hydrophilic block comprises a synthetic polymer.

48. The method of claim 44, wherein the hydrophilic block comprises a natural polymer.

49. The method of claim 44, wherein the hydrophilic block is a variant of the VGVPG (SEQ ID NO:

1).

50. The method of claim 46, wherein the block copolymer further comprises a phosphoryl choline (PC) or poly(ethylene glycol) (PEG) pendant group, wherein the PC or PEG is conjugated to the block copolymer via lysine in the hydrophilic block.

51. The method of claim 47, wherein the synthetic polymer is selected from the group consisting of PEG, PVP (poly vinylpyrrolidinone), polyacrylamide, poly(PEG acrylate), poly (HEMA), poly(acrylic acid), and combinations thereof

52. The method of claim 48, wherein the natural polymer is selected from the group consisting of collagen or collagen derivative, hyaluronic acid, alginate, and combinations thereof.

53. The method of claim 44, wherein the block copolymer further comprises a sequence that promotes proliferation and/or migration of endothelial cells.

54. The method of claim 53, wherein the sequence is selected from the group consisting of RGD, cRGD, SIKVAV (SEQ ID NO:

2), CNP, YIGSRG (SEQ ID NO;

     3), mimetics thereof, and combinations of thereof.

55. The method of claim 44, wherein the block copolymer further comprises a biodegradable linkage between the A and B blocks.

56. The method of claim 55, wherein the biodegradable linkage is selected from the group consisting of poly(lactic acid) (PLA), poly(glycolic acid) (PLGA), polycaprolactone (PCL), poly(3-hydroxybutyric acid (PHB), poly(4-hydroxybutyrate (P4HB), and combinations thereof.

57. The method of claim 41, wherein the medical device is a stent.

58. The method of claim 57, wherein the stent is a bioabsorbable stent.